1
|
Mir M, Aiman W, Baah E, Guron G, Shaaban H. Co-occurrence of High-Risk Myelodysplastic Syndrome With a Complex Karyotype/TP53 Mutation and IgG Lambda Monoclonal Gammopathy of Undetermined Significance. Cureus 2024; 16:e58451. [PMID: 38765410 PMCID: PMC11099498 DOI: 10.7759/cureus.58451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/16/2024] [Indexed: 05/22/2024] Open
Abstract
Myelodysplastic syndrome (MDS) represents a group of hematologic disorders marked by abnormal cellular development in the bone marrow, while monoclonal gammopathy of undetermined significance (MGUS) involves abnormal plasma cells without symptomatic manifestations. This paper presents a compelling case of a 74-year-old Hispanic female diagnosed with a rare combination of high-risk MDS characterized by a complex karyotype and TP53 mutation, alongside IgG lambda MGUS. The patient's clinical presentation included a spectrum of symptoms such as body aches, rash, fever, dyspnea, and bloody watery diarrhea. Initial diagnostic evaluations yielded no significant findings, but subsequent investigations revealed abnormalities in both bone marrow and peripheral blood, indicative of coexisting MDS and MGUS. Chromosomal analysis further confirmed the presence of a complex karyotype with multiple aberrations, notably including 5q deletion. This case underscores the rarity of simultaneous high-risk MDS and MGUS, particularly with the additional complexity of a TP53 mutation and complex karyotype. It underscores the imperative for continued research efforts to elucidate the underlying mechanisms and optimal management strategies for such intricate cases. Moreover, it highlights the therapeutic challenges posed by concurrent MDS and plasma cell disorders, advocating for more aggressive interventions such as stem cell transplantation as potential avenues for improved patient outcomes.
Collapse
Affiliation(s)
- Marwa Mir
- Internal Medicine, Saint Michael's Medical Center, Newark, USA
| | - Wajeeha Aiman
- Internal Medicine, Saint Michael's Medical Center, Newark, USA
| | - Esther Baah
- Internal Medicine, St. George's University School of Medicine, St. George's, GRD
| | - Gunwant Guron
- Hematology and Oncology, Saint Michael's Medical Center, Newark, USA
| | - Hamid Shaaban
- Hematology and Oncology, Saint Michael's Medical Center, Newark, USA
- Hematology and Oncology, New York Medical College, Valhalla, USA
| |
Collapse
|
2
|
Washington NR, Shippey EA, Osswald M. Successful Treatment of Concurrently Diagnosed Multiple Myeloma and Myelodysplastic Syndrome With Isolated Del(5q) With Lenalidomide, Bortezomib, and Dexamethasone. Cureus 2021; 13:e19742. [PMID: 34938621 PMCID: PMC8684828 DOI: 10.7759/cureus.19742] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/18/2021] [Indexed: 11/05/2022] Open
Abstract
Lenalidomide is known to be an effective therapy for multiple myeloma and for myelodysplastic syndrome (MDS) with isolated del(5q). We report the case of a patient simultaneously diagnosed with multiple myeloma and myelodysplastic syndrome with isolated del(5q) who was treated successfully with lenalidomide, bortezomib, and dexamethasone. The treatment achieved a stringent complete response of multiple myeloma and a hematologic and cytogenetic response of MDS in three months. Our experience suggests that standard myeloma induction regimens including lenalidomide and a proteasome inhibitor may be considered for treatment of concurrently diagnosed multiple myeloma and MDS with isolated del(5q) and are safe to use in select patients.
Collapse
Affiliation(s)
| | - Eugen A Shippey
- Hematology/Oncology, Brooke Army Medical Center, San Antonio, USA
| | - Michael Osswald
- Hematology/Oncology, Brooke Army Medical Center, San Antonio, USA
| |
Collapse
|
3
|
Quintini M, Arniani S, Ascani S, Camerini C, Crescenzi B, Di Battista V, Moretti M, Pellanera F, Pierini V, Mecucci C. Identification of two independent clones underlying the co-existence of myelodysplastic syndrome with excess of blasts type 2 and isolated 5q- and smouldering multiple myeloma. Cytopathology 2019; 31:59-62. [PMID: 31295374 DOI: 10.1111/cyt.12752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2018] [Revised: 05/09/2019] [Accepted: 06/30/2019] [Indexed: 11/30/2022]
Affiliation(s)
- Martina Quintini
- Department of Medicine, Section of Hematology and Center for Hemato-Oncology Research CREO, Cytogenetics and Molecular Medicine Laboratory, University of Perugia, Perugia, Italy
| | - Silvia Arniani
- Department of Medicine, Section of Hematology and Center for Hemato-Oncology Research CREO, Cytogenetics and Molecular Medicine Laboratory, University of Perugia, Perugia, Italy
| | - Stefano Ascani
- Department of Medicine, Section of Hematology and Center for Hemato-Oncology Research CREO, Hematopathology Laboratory, University of Perugia, Perugia, Italy
| | - Chiara Camerini
- Department of Medicine, Section of Hematology and Center for Hemato-Oncology Research CREO, Cytogenetics and Molecular Medicine Laboratory, University of Perugia, Perugia, Italy
| | - Barbara Crescenzi
- Department of Medicine, Section of Hematology and Center for Hemato-Oncology Research CREO, Cytogenetics and Molecular Medicine Laboratory, University of Perugia, Perugia, Italy
| | - Valeria Di Battista
- Department of Medicine, Section of Hematology and Center for Hemato-Oncology Research CREO, Cytogenetics and Molecular Medicine Laboratory, University of Perugia, Perugia, Italy
| | - Martina Moretti
- Department of Medicine, Section of Hematology and Center for Hemato-Oncology Research CREO, Cytogenetics and Molecular Medicine Laboratory, University of Perugia, Perugia, Italy
| | - Fabrizia Pellanera
- Department of Medicine, Section of Hematology and Center for Hemato-Oncology Research CREO, Cytogenetics and Molecular Medicine Laboratory, University of Perugia, Perugia, Italy
| | - Valentina Pierini
- Department of Medicine, Section of Hematology and Center for Hemato-Oncology Research CREO, Cytogenetics and Molecular Medicine Laboratory, University of Perugia, Perugia, Italy
| | - Cristina Mecucci
- Department of Medicine, Section of Hematology and Center for Hemato-Oncology Research CREO, Cytogenetics and Molecular Medicine Laboratory, University of Perugia, Perugia, Italy
| |
Collapse
|